Dragon Financial & Investment Group LLC bought a new position in Danaher Co. (NYSE:DHR) in the fourth quarter, HoldingsChannel reports. The fund bought 2,501 shares of the conglomerate’s stock, valued at approximately $232,000. Danaher accounts for approximately 0.2% of Dragon Financial & Investment Group LLC’s investment portfolio, making the stock its 28th biggest position.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. BlackRock Inc. increased its holdings in Danaher by 4.6% in the 4th quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after purchasing an additional 1,789,474 shares in the last quarter. Parnassus Investments CA increased its holdings in Danaher by 0.3% in the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after purchasing an additional 29,381 shares in the last quarter. Flossbach Von Storch AG increased its holdings in Danaher by 17.2% in the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after purchasing an additional 994,902 shares in the last quarter. Dodge & Cox increased its holdings in Danaher by 3.0% in the 2nd quarter. Dodge & Cox now owns 5,250,773 shares of the conglomerate’s stock worth $443,113,000 after purchasing an additional 151,550 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in Danaher by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,630,035 shares of the conglomerate’s stock worth $397,144,000 after purchasing an additional 63,327 shares in the last quarter. 77.05% of the stock is owned by institutional investors and hedge funds.
In related news, SVP Angela S. Lalor sold 42,988 shares of the company’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $102.29, for a total transaction of $4,397,242.52. Following the sale, the senior vice president now owns 82,008 shares in the company, valued at approximately $8,388,598.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP William K. Daniel sold 131,066 shares of the company’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the sale, the executive vice president now owns 270,523 shares in the company, valued at approximately $27,606,872.15. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 237,043 shares of company stock worth $24,194,886. 12.20% of the stock is owned by corporate insiders.
Shares of Danaher Co. (NYSE:DHR) opened at $97.54 on Tuesday. Danaher Co. has a 52-week low of $78.97 and a 52-week high of $104.82. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market capitalization of $67,946.36, a PE ratio of 27.63, a P/E/G ratio of 2.05 and a beta of 1.04.
Danaher (NYSE:DHR) last announced its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, beating the consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company had revenue of $5.09 billion for the quarter, compared to analyst estimates of $4.97 billion. During the same quarter in the prior year, the company earned $1.05 EPS. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. research analysts forecast that Danaher Co. will post 4.37 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Friday, January 26th. Investors of record on Friday, December 29th were given a dividend of $0.14 per share. The ex-dividend date of this dividend was Thursday, December 28th. This represents a $0.56 annualized dividend and a dividend yield of 0.57%. Danaher’s payout ratio is 15.86%.
A number of equities analysts have issued reports on the company. Barclays assumed coverage on Danaher in a report on Thursday, February 15th. They issued an “overweight” rating and a $110.00 target price for the company. Credit Suisse Group upped their price target on Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Morgan Stanley upped their price target on Danaher from $103.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, January 31st. Royal Bank of Canada reiterated a “hold” rating and issued a $98.00 price target on shares of Danaher in a research report on Wednesday, January 31st. Finally, Stifel Nicolaus upped their price target on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Danaher currently has a consensus rating of “Buy” and a consensus price target of $100.68.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/02/20/dragon-financial-investment-group-llc-buys-new-holdings-in-danaher-co-dhr.html.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.